Compare GUT & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GUT | AQST |
|---|---|---|
| Founded | 1999 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 613.8M | 529.4M |
| IPO Year | N/A | 2007 |
| Metric | GUT | AQST |
|---|---|---|
| Price | $5.70 | $4.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $9.33 |
| AVG Volume (30 Days) | 200.5K | ★ 2.0M |
| Earning Date | 01-01-0001 | 11-04-2026 |
| Dividend Yield | ★ 10.93% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $67,430,000.00 |
| Revenue This Year | N/A | $12.09 |
| Revenue Next Year | N/A | $35.73 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 0.77 |
| 52 Week Low | $5.42 | $2.94 |
| 52 Week High | $7.07 | $7.55 |
| Indicator | GUT | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 26.16 | 44.00 |
| Support Level | N/A | $4.51 |
| Resistance Level | $6.29 | $4.69 |
| Average True Range (ATR) | 0.17 | 0.21 |
| MACD | -0.05 | -0.05 |
| Stochastic Oscillator | 6.17 | 8.40 |
Gabelli Utility Trust operates as a diversified closed-end investment management company. The fund's primary objective is the long-term growth of capital and income. To achieve its objective, the fund may invest its assets in common stocks and other securities of foreign and domestic companies involved in providing products, services, or equipment for the generation or distribution of electricity, gas, & water; and telecommunications services or infrastructure operations. It invests in various sectors, of which Electric Integrated, Water, Telecommunications, and U.S. Government Obligations and others.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.